Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2CNS 2Head & Neck 1Genitourinary 1Endocrine 1

Conditions

Urinary Bladder Neoplasms 1Thyroid Cancer, Papillary 1Pancreatic Neoplasms 1Melanoma 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Astrocytoma 1

Interventions

pembrolizumab 23Nivolumab 10Trastuzumab 7Gemcitabine 6Cisplatin 6Cetuximab 6Docetaxel 5spartalizumab 4atezolizumab 4Ipilimumab 4Drug Therapy 4Cyclophosphamide 4Carboplatin 4Capecitabine 4palbociclib 3fludarabine 3cemiplimab 3Radiotherapy 3Magnetic Resonance Spectroscopy 3Erlotinib Hydrochloride 3Bortezomib 3ulixertinib 2trametinib 2sargramostim 2pertuzumab 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2aldesleukin 2Taxes 2TH 302 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pancreatic Neoplasms × tovorafenib × Head & Neck × Clear all
NCT04985604 2025-10-02

Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors

Day One Biopharmaceuticals, Inc.

Phase 2 Terminated
23 enrolled 15 charts
CNSDermatologicEndocrineGastrointestinalGenitourinaryHead & NeckThoracic

Thyroid Cancer, Papillary, Astrocytoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡